Status:
COMPLETED
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Nocturia Associated With Nocturnal Polyuria
Eligibility:
MALE
18-65 years
Brief Summary
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treate...
Eligibility Criteria
Inclusion
- Therapeutic need according to Summary of Product Characteristics
- Written informed consent
Exclusion
- Contraindications according to Summary of Product Characteristics
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00902265
Start Date
February 1 2009
End Date
March 1 2010
Last Update
April 19 2011
Active Locations (140)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site - Pauwelsstraße 30
Aachen, Germany
2
Investigational Site - Sanatoriumstraße 10
Aachen, Germany
3
Investigational Site
Arnsberg, Germany
4
Investigational Site
Bad Bergzaben, Germany